Icatibant

Icatibant selectively blocks the bradykinin B2 receptor, preventing bradykinin from binding and triggering increased vascular permeability. By antagonizing this receptor, the drug reduces the fluid leakage that leads to the swelling characteristic of HAE attacks.

The dose of Icatibant is determined by the prescribing healthcare professional based on the patient’s condition and regulatory guidelines. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, with any additional doses considered only under medical supervision.

Safety data for Icatibant in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider after evaluating the clinical situation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

The primary alternative for acute HAE attacks is C1‑esterase inhibitor replacement therapy. While C1‑inhibitor restores deficient protein levels, Icatibant directly blocks the bradykinin B2 receptor, offering a rapid, subcutaneous option that does not require intravenous infusion. Choice depends on patient preference, access, and clinical response.

Icatibant should be stored refrigerated at 2‑8 °C (36‑46 °F). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. If temporary storage at room temperature is unavoidable, limit exposure to no more than 24 hours.

Icatibant is supplied as a sterile solution for subcutaneous injection. The recommended technique involves cleaning the injection site—usually the abdomen or thigh—and delivering the full dose using a pre‑filled syringe or autoinjector as instructed by a healthcare professional.

Although generally well tolerated, Icatibant can cause serious adverse reactions such as anaphylaxis, severe hypersensitivity, or angioedema unrelated to HAE. Patients should be monitored for signs of systemic allergic response, including difficulty breathing, swelling of the face or throat, and rapid onset of rash, and seek immediate medical attention if they occur.

Icatibant is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should also be avoided in patients who have experienced severe allergic reactions to other bradykinin B2 receptor antagonists. Clinical judgment is required for use in patients with uncontrolled cardiovascular disease.